Selecting a Treatment Regimen
Table 1. Recommendations for the Treatment of MRSA (cont'd) Manifestation
Treatments
Management/ Surgery
of Therapy Duration
Agent (Brand)
Skin and Soft Tissue Infections (SSTI)* - Outpatients (continued) ,
others) Purulent cellulitis
(cellulitis associated with purulent drainage or exudate in the absence of a drainable abscess)
Empiric therapy for CA-MRSA (A-II).
No therapy for β-hemolytic streptococci (A-II).
Treat for 5-10 days.†
Clindamycin (Cleocin®
TMP-SMX‡ (Bactrim®
)
Antibiotics Adult Dose
300-450 mg PO tid
1-2 DS tab PO bid
Doxycycline 100 mg PO bid
Minocycline (Minocin®
)
Linezolid (Zyvox®
) Non-purulent cellulitis
(cellulitis with no purulent drainage or exudate and no associated abscess)
Empiric therapy for β-hemolytic streptococci (A-II) and for CA-MRSA in patients who fail to respond to β-lactam therapy or those with systemic toxicity.
β-lactam (eg, cephalexin,‡ dicloxacillin)
Treat for 5-10 days.†
β-lactam (eg, amoxicillin‡
200 mg x 1, then 100 mg PO/IV bid
600 mg PO bid 500 mg PO qid
and TMP-SMX‡ (Bactrim®
Linezolid (Zyvox®
others)
)
a tetracycline )
Clindamycin (Cleocin®
, ) or
Amox: 500 mg PO tid See above for TMP-SMX‡ and tetracycline dosing
600 mg PO bid
300-450 mg PO tid
NOTE: The use of rifampin as a single agent or as adjunctive therapy for the treatment of SSTI is NOT recommended (A-III).
2
